ArticleMedicine2026
Misoprostol combined with oxytocin versus oxytocin alone in improving cervical Bishop score during term induction of labor: A retrospective analysis.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to investigate the effect of misoprostol combined with oxytocin versus oxytocin alone on improving the cervical Bishop score during term labor induction and its impact on delivery outcomes. A retrospective analysis was conducted on 200 pregnant women who underwent term labor induction and met the inclusion criteria at Ningcheng Central Hospital, Chifeng, between Decemeber 2024 and May 2025. According to different clinical medication regimens, they were divided into a control group (oxytocin alone, n = 100) and a study group (misoprostol combined with oxytocin, n = 100). Baseline data, improvements in cervical Bishop score, labor-related indicators, and delivery outcomes were collected for both groups, and subgroup analyses were performed. There were no statistically significant differences in baseline data between the 2 groups (P > .05). After 12 hours of intervention, the improvement in Bishop score was significantly greater in the study group compared with the control group (Δ Bishop score 3.5 ± 1.2 vs 2.4 ± 1.0, P < .001), with a higher overall effective rate (87.0% vs 71.0%, P = .012). The study group also showed significantly shorter times from medication to onset of labor (8.4 ± 2.9 vs 11.8 ± 3.5 hours) and for the first stage of labor (7.2 ± 2.8 vs 9.6 ± 3.2 hours) (both P < .001). The vaginal delivery rate in the study group was 86.0%, higher than 72.0% in the control group (P = .015). Subgroup analysis indicated that the combined regimen had advantages in both primiparas and multiparas, as well as in women at 37 to 39 weeks or ≥40 weeks of gestation, with more pronounced benefits in primiparas and those at 37 to 39 weeks. Misoprostol combined with oxytocin during term labor induction can significantly improve cervical ripening, shorten the time from medication to labor onset and the first stage of labor, and increase the vaginal delivery rate, showing high clinical application value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.